DrugCombination product

Belzupacap sarotalocan clinical trials

Also written AU-011.

studies test it: 5
open now: 1
in phase 3: 1
first study started: 2017

How each study uses belzupacap sarotalocan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the belzupacap sarotalocan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

belzupacap sarotalocan: 1

Development codes

AU-011: 5

Studies by the year they started

5 studies that test it; most in 2017 (1)

Studies that test belzupacap sarotalocan, by start year
Year	Studies
2017	1
2020	1
2022	1
2023	1
2024	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 3
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Uveal Melanoma: 3
Non-Muscle Invasive Bladder Neoplasms: 1
Eye Neoplasms: 1

Who runs them

Industry 5 · Other 0

Aura Biosciences (5)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test belzupacap sarotalocan, phase 3 first.

Nov 2027A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaPhase 3 · Aura Biosciences
Nov 2026Suprachoroidal Administration in Subjects With Metastases to the ChoroidPhase 2 · Aura Biosciences
Mar 2027A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerPhase 1 · Aura Biosciences

Studies

Open first, then newest update. How each study uses belzupacap sarotalocan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Codes

What other systems call belzupacap sarotalocan · ClinicalTrials.gg INT016337

UNII (FDA) DK0ZGA5Y2RBELZUPACAP SAROTALOCANOne source FDA
NCI Thesaurus C137951Belzupacap SarotalocanOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	DK0ZGA5Y2R	BELZUPACAP SAROTALOCAN	One source FDA
NCI Thesaurus	C137951	Belzupacap Sarotalocan	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.